CN111000902A - Traditional Chinese medicine tincture for treating acute soft tissue injury and preparation method thereof - Google Patents
Traditional Chinese medicine tincture for treating acute soft tissue injury and preparation method thereof Download PDFInfo
- Publication number
- CN111000902A CN111000902A CN202010006502.0A CN202010006502A CN111000902A CN 111000902 A CN111000902 A CN 111000902A CN 202010006502 A CN202010006502 A CN 202010006502A CN 111000902 A CN111000902 A CN 111000902A
- Authority
- CN
- China
- Prior art keywords
- weight
- borneol
- traditional chinese
- chinese medicine
- soft tissue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940098465 tincture Drugs 0.000 title claims abstract description 47
- 239000003814 drug Substances 0.000 title claims abstract description 46
- 208000026137 Soft tissue injury Diseases 0.000 title claims abstract description 33
- 230000001154 acute effect Effects 0.000 title claims abstract description 30
- 238000002360 preparation method Methods 0.000 title claims abstract description 6
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 33
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims abstract description 33
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims abstract description 33
- 229940116229 borneol Drugs 0.000 claims abstract description 33
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims abstract description 33
- 235000015912 Impatiens biflora Nutrition 0.000 claims abstract description 27
- 239000000463 material Substances 0.000 claims abstract description 22
- 241000208966 Polygala Species 0.000 claims abstract description 11
- 244000018716 Impatiens biflora Species 0.000 claims description 33
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 32
- 241001638289 Polygala japonica Species 0.000 claims description 18
- 208000002193 Pain Diseases 0.000 claims description 15
- 239000006228 supernatant Substances 0.000 claims description 10
- 230000008961 swelling Effects 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 239000000706 filtrate Substances 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 7
- 238000011049 filling Methods 0.000 claims description 5
- 238000007789 sealing Methods 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 206010061218 Inflammation Diseases 0.000 claims description 3
- 238000000227 grinding Methods 0.000 claims description 3
- 230000004054 inflammatory process Effects 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims description 3
- 238000000967 suction filtration Methods 0.000 claims description 3
- 239000008213 purified water Substances 0.000 claims description 2
- 206010042674 Swelling Diseases 0.000 claims 1
- 241000700159 Rattus Species 0.000 abstract description 27
- 210000004369 blood Anatomy 0.000 abstract description 9
- 239000008280 blood Substances 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 9
- 230000003213 activating effect Effects 0.000 abstract description 5
- 230000017531 blood circulation Effects 0.000 abstract description 4
- 238000002474 experimental method Methods 0.000 abstract description 2
- 238000009499 grossing Methods 0.000 abstract description 2
- 238000012360 testing method Methods 0.000 abstract description 2
- 240000000917 Impatiens balsamina Species 0.000 abstract 1
- 210000002381 plasma Anatomy 0.000 description 13
- 235000019485 Safflower oil Nutrition 0.000 description 9
- 210000001087 myotubule Anatomy 0.000 description 9
- 239000003813 safflower oil Substances 0.000 description 9
- 235000005713 safflower oil Nutrition 0.000 description 9
- 230000017074 necrotic cell death Effects 0.000 description 8
- 230000008595 infiltration Effects 0.000 description 7
- 238000001764 infiltration Methods 0.000 description 7
- 210000004969 inflammatory cell Anatomy 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 6
- 206010063560 Excessive granulation tissue Diseases 0.000 description 5
- 210000001126 granulation tissue Anatomy 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 206010014080 Ecchymosis Diseases 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 210000003141 lower extremity Anatomy 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 210000000707 wrist Anatomy 0.000 description 4
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 208000021945 Tendon injury Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 230000008736 traumatic injury Effects 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- 241000233805 Phoenix Species 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000010100 anticoagulation Effects 0.000 description 2
- 210000000702 aorta abdominal Anatomy 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 230000002951 depilatory effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000000703 high-speed centrifugation Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 210000003314 quadriceps muscle Anatomy 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010010726 Conjunctival oedema Diseases 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 241000146384 Glaux Species 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010020741 Hyperpyrexia Diseases 0.000 description 1
- 241001495448 Impatiens <genus> Species 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- 229930192627 Naphthoquinone Natural products 0.000 description 1
- 241000475481 Nebula Species 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 208000004078 Snake Bites Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 235000005155 Tanacetum balsamita Nutrition 0.000 description 1
- MJOQJPYNENPSSS-XQHKEYJVSA-N [(3r,4s,5r,6s)-4,5,6-triacetyloxyoxan-3-yl] acetate Chemical compound CC(=O)O[C@@H]1CO[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O MJOQJPYNENPSSS-XQHKEYJVSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 231100000895 deafness Toxicity 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 229930190166 impatien Natural products 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 150000002791 naphthoquinones Chemical class 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 150000008130 triterpenoid saponins Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/69—Polygalaceae (Milkwort family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Physical Education & Sports Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a traditional Chinese medicine tincture for treating acute soft tissue injury, which is prepared from 1 part by weight of impatiens balsamina, 1 part by weight of Japanese polygala and auxiliary materials, wherein the auxiliary materials comprise 1 part by weight of borneol. The invention also provides a preparation method of the traditional Chinese medicine tincture. The traditional Chinese medicine tincture has the effects of activating blood circulation to dissipate blood stasis, clearing and activating the channels and collaterals and smoothing qi and blood, and achieves ideal effects through rat animal experiments and clinical tests.
Description
Technical Field
The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine tincture for treating acute soft tissue injury and a preparation method thereof.
Background
Acute soft tissue injury refers to microcirculation disturbance and aseptic inflammation after soft tissue or skeletal muscle is subjected to direct or indirect brute force and other wounds, and is mainly represented by swelling and pain of affected parts, the common phenomenon in daily life is that patients mostly use safflower oil for smearing, but the tincture prepared by the applicant in clinical practice for many years not only has better curative effect but also has the advantages that ① medicine directly reaches the focus of a disease, is absorbed quickly and directly, is reflected by most clinical patients, can feel pain relieved at the first time after taking the tincture, ② is high in safety, toxic and side effects are avoided, skin irritation is small, anaphylactic reaction is not easy to occur, ③ smell irritation is small, and the tincture is easy to accept.
Disclosure of Invention
The invention aims to provide a traditional Chinese medicine tincture for treating acute soft tissue injury.
The invention aims to realize the following technical scheme that a traditional Chinese medicine tincture for treating acute soft tissue injury is prepared from 1-10 parts by weight of impatiens balsamina, 1-10 parts by weight of polygala japonica and auxiliary materials. The auxiliary materials comprise 0.1 to 1 weight portion of borneol.
In a preferred embodiment, the weight ratio of the impatiens balsamina to the polygala japonica is 1: 1.
In a preferable embodiment, the weight ratio of the impatiens balsamina, the Japanese polygala and the borneol is 1:1: 0.24.
In a preferred embodiment, the traditional Chinese medicine tincture for treating acute soft tissue injury is prepared from 1 part by weight of impatiens balsamina, 1 part by weight of polygala japonica and auxiliary materials. The auxiliary materials comprise 0.24 weight part of borneol.
In a preferred embodiment, the traditional Chinese medicine tincture for treating acute soft tissue injury is prepared from 1 part by weight of impatiens balsamina, 2 parts by weight of polygala japonica and auxiliary materials. The auxiliary materials comprise 0.24 weight part of borneol.
In a preferred embodiment, the traditional Chinese medicine tincture for treating acute soft tissue injury is prepared from 2 parts by weight of impatiens balsamina, 3 parts by weight of polygala japonica and auxiliary materials. The auxiliary materials comprise 0.5 weight part of borneol.
In a preferred embodiment, the traditional Chinese medicine tincture for treating acute soft tissue injury is prepared from 4 parts by weight of impatiens balsamina, 5 parts by weight of polygala japonica and auxiliary materials. The auxiliary materials comprise 1 part by weight of borneol.
The traditional Chinese medicine tincture for treating acute soft tissue injury is preferably used for treating inflammation caused by acute soft tissue injury.
The traditional Chinese medicine tincture for treating acute soft tissue injury is preferably used for treating swelling caused by acute soft tissue injury.
As a preferred embodiment, the traditional Chinese medicine tincture for treating acute soft tissue injury is specifically used for treating pain caused by acute soft tissue injury.
The invention also aims to provide a preparation method of the traditional Chinese medicine tincture for treating acute soft tissue injury, which comprises the following steps:
s1, preparing balsamine, Japanese polygala and borneol according to the parts by weight, and respectively screening and grinding the balsamine, the Japanese polygala and the borneol into powder;
s2, feeding impatiens balsamina and polygala japonica respectively, adding 10 times of purified water for water decoction, standing, taking supernate, and performing suction filtration by using a suction filter to obtain impatiens balsamina filtrate and polygala japonica filtrate respectively;
s3, mixing the impatiens balsamina extract filtrate and the herba Polygalae Japonicae extract with 1 time of 75% ethanol, standing, and concentrating the supernatant to obtain herba Polygalae Japonicae high-concentration extract and herba Impatientis high-concentration extract;
s4, mixing the high-concentration polygala japonica extract and the high-concentration balsamine extract;
s5, adding the borneol alcohol solution into the mixed liquid medicine and stirring to uniformly mix the borneol alcohol solution and the borneol alcohol solution;
s6, standing and filtering;
and S7, filtering the liquid medicine by using a filter, filling and sealing.
In a preferred method, the concentration of the supernatant in step S3 is repeated by using a rotary evaporator.
In a preferred method, the borneol alcohol solution is prepared from borneol: 75% ethanol (12: 55 (weight to volume ratio g/ml)).
The prescription of the traditional Chinese medicine tincture and the pharmacological effects of the raw materials are as follows:
according to traditional Chinese medicine, soft tissue injury belongs to tendon injury, so-called 'obstruction leading to pain', main pathogenesis of injury of channels and collaterals and qi and blood stasis is that the main pathogenesis of the soft tissue injury is blood circulation activating, blood stasis dissipating, tendon relaxing and collateral activating, and qi and blood smoothing are mainly clinically treated. In the invention, the impatiens balsamina: the main components are impatiens naphthoquinone (MNQ-1) and the like; the pharmacological actions include antibacterial, antiinflammatory, analgesic, antiallergic, skin penetration promoting, and antioxidant effects. Has effects in promoting blood circulation, relieving swelling, dredging channels, and relieving pain, and can be used for treating traumatic injury, amenorrhea, abdominal pain, puerperal blood stasis, and pain in waist and hypochondrium. Japanese milkwort herb: the main components are triterpenoid saponin, resin, fatty oil, polygalacturol, tetraacetate and the like; the pharmacological actions are activating blood circulation to dissipate blood stasis, detoxifying and relieving pain, eliminating phlegm and relieving cough. Can be used for treating cough with excessive phlegm, sore throat by oral administration; it can be used for treating traumatic injury, furuncle, and snake and insect bite. Borneol: the main components are borneol, camphor and the like; the pharmacological actions are antibacterial, antifungal, anti-inflammatory and analgesic. It can be used for treating fever, hyperpyrexia, coma, apoplexy, phlegm syncope, epilepsy, summer-heat, dampness, obstruction of orifices, pharyngitis, deafness, aphtha, dental swelling, skin sore, carbuncle, hemorrhoid, conjunctival congestion, swelling and pain, nebula, ophthalmopathy, and traumatic injury.
Detailed Description
Example a process for preparing a Chinese medicinal tincture of the invention
Taking 50g of impatiens balsamina, 50g of Japanese polygala and 12g of borneol, and respectively screening and grinding into powder;
decocting 50g of impatiens balsamina with 500g of water, standing, filtering, taking supernatant, performing suction filtration by using a suction filter, concentrating the filtrate under reduced pressure to 250mL, adding 75% ethanol according to the proportion of 1:1 (250 mL: 250mL), mixing, standing, taking supernatant, repeatedly concentrating and purifying to 50mL by using a rotary evaporator to obtain an impatiens balsamina high-concentration extracting solution;
decocting herba Polygalae Japonicae 50g with water 500g, standing, filtering, collecting supernatant, vacuum filtering with a filter, concentrating the filtrate under reduced pressure to 250mL, adding 75% ethanol at a ratio of 1:1 (250 mL: 250mL), mixing, standing, collecting supernatant, repeatedly concentrating with rotary evaporator, and purifying to 50mL to obtain high concentration herba Polygalae Japonicae extract;
mixing the high-concentration polygala japonica extract and the high-concentration garden balsam extract, adding 12g of borneol into 55mL of 75% ethanol, adding into the mixed extract, stirring for 10-20 min to dissolve, standing, filtering by using a filter, filling and sealing.
Example two histomorphological effects of the Chinese medicinal tincture on acute soft tissue injury of rats
1.1 materials
Laboratory animal
40 healthy SD rats with half male and female, weight (300+20) g, provided by Beijing Wittiulihua laboratory animal technology Co., Ltd., production license: SYXK (yu) 2015-: SCXK (Kyoto) 2016-.
Medicaments and agents
Dried Japanese polygala, dried balsamine and borneol are purchased from Anhui Bozhou medicinal material market, and safflower oil (Liangjiafu (Guangdong) pharmaceutical industry Co., Ltd., approved document: Chinese medicine standard character Z20093693). 75% ethanol (Takara Shuzo chemical Co., Ltd., lot: 1009221). Pentobarbital sodium salt (produced by national medicine group chemical reagent Co., Ltd., batch number: XW20180825), depilatory cream (Guangzhou Chunyan cosmetics Co., Ltd., approved document number: national cosmetic character G20150515), 4% paraformaldehyde (produced by Wuhan doctor Ded bioengineering Co., Ltd., batch number: 13K17B68), IL-6 enzyme linked immunosorbent assay kit (produced by R & D Co., Ltd., batch number: 201902), IL-17A enzyme linked immunosorbent assay kit (produced by Darwin Co., Ltd., batch number: E20190301A),
1.2 Experimental methods
Healthy SD rat 40 fruitsThe hair of the left hind leg rat is removed by depilatory cream one day before the test, 10 rats are randomly selected as blank groups, and the rats are molded in half of the female group and half of the male group. The left hind leg of a rat is fixed in a knee extending and naked dorsiflexion right angle mode, a 250g weight is used for hitting the rectus femoris above the styloid process of the left hind leg of the rat through a free falling body at the upper end of a vertical hard paper cylinder of 5 multiplied by 4 multiplied by 25cm, the rectus femoris muscle is hit for 8 times by the same person continuously, the hit part is obviously red and swollen, no fracture or dislocation exists, the skin is not damaged, and no other abnormal conditions exist, so that the model building success is determined. After the model building is successful, rats are divided into a model group, a safflower oil group and a golden phoenix tincture group obtained in the first embodiment according to a weight interval and semi-random sex, each group comprises 10 rats, the groups and a blank group are marked on the back by picric acid and are fed in cages, and 2-3 rats are fed in each cage, so that the animals are prevented from being attacked by each other after being injured, and the experimental result is influenced. The drug administration is started 24h after the model building is successful, and except for a blank group and a model group, each group is respectively and uniformly smeared on the soft tissue injury part of the left hind limb of a rat by 0.5 ml/time of each tested drug, and the drug administration area is about 5cm2The administration was continued once in the morning and once in the evening for 5 days.
After the blood is taken at the 5 th day, the 1cm central part of the model wound is selected3Muscle tissues are fixed by 4% paraformaldehyde, embedded by conventional paraffin, slices are 4-5 mu m thick, HE staining is carried out, observation is carried out under an optical microscope, and 5 high power lens fields are randomly selected for each slice to carry out observation and scoring.
On day 5 after administration, the muscle tissue sections of the rats in the blank group had intact tissue structures, no inflammatory cell infiltration, no bleeding, no tissue atrophy, no degenerative necrosis, and normal arrangement of muscle fibers. The rat muscle tissue section of the model group can show diffuse infiltration of inflammatory cells in large area, unclear cell boundary, extensive water sample degeneration, large-area degeneration and necrosis of muscle fibers, larger interval between muscle fibers, granulation tissue and tissue necrosis. The muscle tissue sections of rats in the Jinfeng tincture group have no inflammatory cell infiltration, small cell boundaries are unclear, muscle fibers are uniformly and orderly arranged, granulation tissues are not seen, and tissue necrosis is seen. Compared with the Jinfeng tincture group, the rat muscle tissue section containing safflower oil has the advantages that inflammatory cell infiltration range is large, most cells are not limited, a small part of muscle fibers are arranged uniformly and orderly, intervals among the muscle fibers are large, large-area granulation tissue hyperplasia can be seen, and tissue necrosis can be seen.
Grading standard: no inflammatory cell infiltration and necrosis, uniform and tidy arrangement of muscle fibers, and 0 point of score; inflammatory cell infiltration, small necrosis, irregular arrangement of partial muscle fibers, a small amount of granulation tissues and 1 point of score; large area inflammatory cell infiltration, obvious necrosis, irregular arrangement of most muscle fibers, a large amount of granulation tissues seen, 2 points.
The results are shown in table 1, with a significant increase in histopathological score (P < 0.01) in the remaining rats in each group compared to the blank group; compared with the model group, the histopathological scores of the positive safflower oil group and the golden phoenix tincture group are obviously reduced (P is less than 0.01); compared with the safflower oil, the difference of the Jinfeng tincture group has no statistical significance (P is more than 0.05).
TABLE 1 histopathological Scoring of the groups of rats: (
n＝10)
Note: comparison with blank group△△P is less than 0.01; p < 0.01 compared to model group.
Example III Effect of the tincture of the invention on plasma viscosity
4h after the last administration, 40 rats are subjected to whole abdominal aorta blood sampling, EDTA anticoagulation and high-speed centrifugation, centrifuge tubes are placed in a constant-temperature water bath kettle at 37 ℃, the rise height of the plasma in 10s is measured by capillary glass tubes with the inner diameter of 1mm, the amount of each group of measured samples is 8, and in straight, long and round capillaries, the relationship between the flow rate Q of fluid, the tube radius R, the tube length L, the fluid viscosity η and the pressure difference P at two ends of the capillary is that Q is pi multiplied by R4 multiplied by delta P/(8 η L), therefore, the rise height of the plasma in the capillary glass tubes in 10s is inversely proportional to the plasma viscosity.
The results are shown in Table 2, and the plasma viscosity of the model group rats is obviously increased (P < 0.01) compared with that of the blank group; compared with the model group, the blood plasma viscosity of the rats in the Jinfeng tincture group is obviously reduced (P is less than 0.05); compared with the safflower oil, the blood viscosity of the Jinfeng tincture group is reduced, but the difference is not statistically significant (P is more than 0.05).
Table 2 plasma viscosity comparison of rats in each group
Note: comparison with blank group△△P is less than 0.01; p < 0.05 compared to model group.
Example four anti-inflammatory action of the Chinese medicinal tincture of the invention
4h after the last administration, 40 rats were subjected to whole abdominal aorta blood sampling, EDTA anticoagulation, high-speed centrifugation, and then the plasma IL-6 and IL-17A content of the rats with acute soft tissue injury was measured according to the instruction. Wherein the amount of IL-6 in each group is 10, and the amount of IL-17A in each group is 8.
The results are shown in tables 3 and 4, and compared with the blank group, the plasma IL-6 and IL-17A content of the rats in the model group is increased (P is less than 0.05); compared with the model group, the content of IL-6 and IL-17A in the blood plasma of rats in the safflower oil group and the Jinfeng tincture group is reduced (P is less than 0.05); compared with the safflower oil, the difference of the IL-6 and IL-17A contents in the blood plasma of the Jinfeng tincture group has no statistical significance (P is more than 0.05).
TABLE 3 comparison of the plasma inflammatory factor (IL-6) content in the groups
Note: comparison with blank group△P＜0.05△△P is less than 0.01; p < 0.05 × P < 0.01 compared to model group.
TABLE 4 comparison of the plasma inflammatory factor (IL-17A) content in the groups
Note: comparison with blank group△P is less than 0.05; p < 0.05 compared to model group.
Example five clinical trials of the Chinese medicinal tincture of the invention
4.1 general data
In the study, data of 32 patients receiving acute soft tissue injury treatment in a hospital from 9 months 2018 to 9 months 2019 are selected as study objects, wherein 20 male patients and 12 female patients are selected, the overall age is 6-88 years, and the average age is 24 years. Of the 32 patients with acute soft tissue injury, 2 patients aged 20 years or less, 28 patients aged 21-46 years or more, and 2 patients aged 47 years or more. All patients had not received other forms of treatment before visiting my hospital.
4.2 diagnostic criteria
① meets the definition of ② years ③ from 6 to 80 years of age to no more than 3 days of clinical diagnosis in "science of tendon injury" and "surgery" of traditional Chinese medicine
4.3 methods of treatment and Care
The tincture is used, 10g of impatiens balsamina is weighed, distilled water is decocted in 1:10 for alcohol extraction, 75% ethanol is added in 1:1, the mixture is stood and kept for supernatant fluid concentration, 10g of Japanese polygala is weighed and added, borneol is dissolved in alcohol, and then two extracting solutions 1:1, stirring and dissolving the mixed solution, filling and sealing to obtain the product. The tincture is applied to affected part uniformly, once a day in the morning and evening, and 3 days as 1 course of treatment.
The nursing method comprises the following steps: when the medicine is used, other medicines are not used on the affected part. The patient keeps physical and mental pleasure and does not perform excessive movement.
4.4 therapeutic criteria
According to the symptoms of acute soft tissue injury after medication, the curative effect is divided into three categories: and (3) curing: the local pain disappears, the swelling, ecchymosis and tenderness disappear, and the function recovers the level before injury. The effect is shown: the local pain and the tenderness are quickly relieved, the swelling and ecchymosis are basically eliminated, and the function is recovered to be normal. The method has the following advantages: the local pain, tenderness, swelling and ecchymosis subside, and the functional activity is obviously recovered. And (4) invalidation: after 3 days of treatment, symptoms and signs are not obvious.
4.5 therapeutic results
Among 32 patients receiving treatment, 28 patients have obvious recovery of acute soft tissue injury, accounting for 87.5 percent of the total number of patients; the change of the disease condition of 3 patients is small, accounting for 9.375 percent of the number of patients. The illness state of 1 patient is unchanged, accounting for 3.125 percent of the number of patients; the total effective rate reaches 96.875%.
4.6 typical cases
Dingzhi, 54 years old, male, worker, 2.2019, 21 days of first diagnosis. The patient had pain in the right wrist for one day after the heavy physical work. And (4) checking: the patient's right wrist is bluish purple, swollen, and the pain is aggravated by pressing or moving. And (3) Western diagnosis: acute soft tissue injury of the right wrist. Traditional Chinese medicine diagnosis: tendon injury. The tincture is used, 10g of impatiens balsamina is weighed, distilled water is decocted in 1:10 for alcohol extraction, 75% ethanol is added in 1:1, the mixture is stood and kept for supernatant fluid concentration, 10g of Japanese polygala is weighed and added, borneol is dissolved in alcohol, and then two extracting solutions 1:1, stirring and dissolving the mixed solution, filling and sealing to obtain the product. The tincture is applied to affected part uniformly, once a day in the morning and evening, and 3 days as 1 course of treatment. After 1 treatment course, the patients' local pain and tenderness of the wrists are quickly relieved, the swelling and ecchymosis are basically eliminated, and the functions are recovered to be normal. The treatment is repeated after the medicine is stopped for 1 week, and the clinical examination is normal.
The above examples are for illustrative purposes only, and the scope of the present invention is not limited thereto. Modifications will be apparent to those skilled in the art and the invention is limited only by the scope of the appended claims.
Claims (14)
1. A traditional Chinese medicine tincture for treating acute soft tissue injury is characterized in that: is prepared from 1-10 parts by weight of impatiens balsamina, 1-10 parts by weight of polygala japonica and auxiliary materials.
2. The traditional Chinese medicine tincture as claimed in claim 1, wherein the auxiliary materials comprise 0.1-1 parts by weight of borneol.
3. The traditional Chinese medicine tincture of claim 1 or 2, wherein the weight ratio of the impatiens balsamina to the polygala japonica is 1: 1.
4. The traditional Chinese medicine tincture as claimed in claim 2, wherein the weight ratio of the impatiens balsamina, the Japanese polygala and the borneol is 1:1: 0.24.
5. The traditional Chinese medicine tincture as claimed in claim 2, which is prepared from 1 part by weight of impatiens balsamina, 1 part by weight of polygala japonica and auxiliary materials, wherein the auxiliary materials comprise 0.24 part by weight of borneol.
6. The traditional Chinese medicine tincture as claimed in claim 2, which is prepared from 2 parts by weight of impatiens balsamina, 3 parts by weight of polygala japonica and auxiliary materials, wherein the auxiliary materials comprise 0.5 part by weight of borneol.
7. The traditional Chinese medicine tincture as claimed in claim 2, which is prepared from 4 parts by weight of impatiens balsamina, 5 parts by weight of polygala japonica and auxiliary materials, wherein the auxiliary materials comprise 1 part by weight of borneol.
8. A method of preparing the traditional Chinese medicine tincture of claim 1 or 2, which comprises the following steps:
s1, preparing balsamine, Japanese polygala and borneol according to the parts by weight, and respectively screening and grinding the balsamine, the Japanese polygala and the borneol into powder;
s2, feeding impatiens balsamina and polygala japonica respectively, adding 10 times of purified water for water decoction, standing, taking supernate, and performing suction filtration by using a suction filter to obtain impatiens balsamina filtrate and polygala japonica filtrate respectively;
s3, mixing the impatiens balsamina extract filtrate and the herba Polygalae Japonicae extract with 1 time of 75% ethanol, standing, and concentrating the supernatant to obtain herba Polygalae Japonicae high-concentration extract and herba Impatientis high-concentration extract;
s4, mixing the high-concentration polygala japonica extract and the high-concentration balsamine extract;
s5, adding the borneol alcohol solution into the mixed liquid medicine and stirring to uniformly mix the borneol alcohol solution and the borneol alcohol solution;
s6, standing and filtering;
and S7, filtering the liquid medicine by using a filter, filling and sealing.
9. The method according to claim 3, wherein the concentration of the supernatant of the step S3 is repeated concentration by a rotary evaporator.
10. The preparation method of claim 3, wherein the borneol alcohol solution is prepared from borneol: 75% ethanol (12: 55 g/ml).
11. The use of the traditional Chinese medicine tincture of any one of claims 1-7 in a medicament for treating acute soft tissue injury.
12. The use according to claim 11, wherein the medicament is for the treatment of inflammation caused by acute soft tissue injury.
13. The use according to claim 11, wherein the medicament is for the treatment of pain resulting from acute soft tissue injury.
14. The use according to claim 11, wherein the medicament is for the treatment of swelling caused by acute soft tissue injury.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010006502.0A CN111000902B (en) | 2020-01-03 | 2020-01-03 | Traditional Chinese medicine tincture for treating acute soft tissue injury and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010006502.0A CN111000902B (en) | 2020-01-03 | 2020-01-03 | Traditional Chinese medicine tincture for treating acute soft tissue injury and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111000902A true CN111000902A (en) | 2020-04-14 |
| CN111000902B CN111000902B (en) | 2021-09-21 |
Family
ID=70120324
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010006502.0A Active CN111000902B (en) | 2020-01-03 | 2020-01-03 | Traditional Chinese medicine tincture for treating acute soft tissue injury and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111000902B (en) |
-
2020
- 2020-01-03 CN CN202010006502.0A patent/CN111000902B/en active Active
Non-Patent Citations (3)
| Title |
|---|
| 史书达: "《常见病自我治疗小偏方》", 30 June 2016, 内蒙古科学技术出版社 * |
| 国家药典委员会: "《中华人民共和国药典临床用药须知：2015版.中药饮片卷》", 30 September 2017, 中国医药科技出版社 * |
| 钟士超: "《大理白族药》", 31 December 2013, 云南民族出版社 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111000902B (en) | 2021-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2006076844A1 (en) | Traditional chinese medicament for treating injuries from falls, rheumatism and ostealgia and method for manufacture thereof | |
| CN101143166B (en) | Medicine for swelling and relieving pain and its preparation method and application | |
| CN1092981C (en) | Medicine for curing arthralgia-syndrome resulted from wind,cold and dampness and its preparation method | |
| CN108324816A (en) | A kind of anaesthetic and preparation method thereof for treating rheumatic arthritis | |
| CN103071134B (en) | External preparation for treating rheumatic arthrodynia and traumatic pain and swelling and preparation method thereof | |
| CN1709302A (en) | Chinese medicine formulation for treating chronic pelvic inflammation and its preparing method | |
| CN111000902B (en) | Traditional Chinese medicine tincture for treating acute soft tissue injury and preparation method thereof | |
| CN109528917B (en) | Korean medicinal composition for treating rheumatoid arthritis and preparation method of cream thereof | |
| CN1689591A (en) | Chinese medicine for treating gynopathy and its preparing process | |
| CN1319549C (en) | Method for extracting general iridoid glycoside from 'Duyiwei' of Tibet medicine and application | |
| CN1739682A (en) | Nudiflorous beautyberry soft capsule for body cavity and its prepn | |
| CN106880654B (en) | Application of panax japonicus extract in preparing medicine for treating rhinitis and composition | |
| CN111686224A (en) | Pure Chinese herbal medicine extraction compound oil agent for adjuvant therapy of hypertension, hyperglycemia and hyperlipidemia | |
| CN115414295B (en) | Compound plant acne-removing mite-inhibiting composition and preparation method and application thereof | |
| CN101040977B (en) | Medicine for treating prostate disease and method for preparing same | |
| CN105997848A (en) | Tangut anisodus radix and musk gel and preparation method thereof | |
| CN1301727C (en) | Externally applied Chinese medicine preparation for treating skin disease and its preparation method | |
| CN110812401A (en) | Traditional Chinese medicine composition for soft tissue injury and detection method thereof | |
| CN103341044A (en) | Itching-relieving compound preparation and preparation method thereof | |
| CN104274540B (en) | Chinese medicine composition, preparation method and use containing tripterygium wilfordii | |
| CN114028483B (en) | Pharmaceutical composition and preparation for treating chronic soft tissue injury | |
| CN101129604A (en) | Antihypelipidemic traditional Chinese medicine and method of producing the same | |
| CN1883592A (en) | Gel for treating rheumatism and headache and method for preparing same | |
| EP3441077A1 (en) | Pharmaceutical product for treating ankylosing spondylitis and combined immune defect, and preparation and application thereof | |
| CN104623050B (en) | A kind of medicament for the treatment of corticosteroid femur head necrosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |